Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Bets On Mexican Private Label Growth With Laboratorios Diba Buy

This article was originally published in The Tan Sheet

Executive Summary

Perrigo is betting the Mexican store-brand market will grow the way private label did in the U.S. 20 years ago, with its $25 million acquisition of Laboratorios Diba

You may also be interested in...



Perrigo Makes Softgel Move As Mylan Continues Takeover Play

Acquiring Patheon’s Mexico plant not only adds softgel capabilities to Perrigo’s operations but also boosts its value as an acquisition target. The firm continues integrating Omega Pharma’s operations and managing its OTC private label and other businesses as Mylan presses for Perrigo shareholders to consider its bid.

Perrigo Makes Softgel Move As Mylan Continues Takeover Play

Acquiring Patheon’s Mexico plant not only adds softgel capabilities to Perrigo’s operations but also boosts its value as an acquisition target. The firm continues integrating Omega Pharma’s operations and managing its OTC private label and other businesses as Mylan presses for Perrigo shareholders to consider its bid.

Perrigo Will Acquire Orion Labs To Reach Australian Market

Perrigo's pending $49 million acquisition of Orion Laboratories marks the private labeler's entrance into the promising Australian OTC market and adds a "beachhead" for the firm's continued global expansion, analysts say

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS102198

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel